PTEN mutation

News alerts, weekly reports and conference planners

Entrez ID:

5728

Related biomarkers:

‹

›

PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	bicalutamide Sensitive: B - Late Trials bicalutamide Sensitive : B	bicalutamide Sensitive: B - Late Trials bicalutamide Sensitive : B
PTEN mutation	Colorectal Cancer	PTEN mutation	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B	GDC-0032 Resistant: B - Late Trials GDC-0032 Resistant : B
PTEN mutation	Estrogen Receptor Positive Breast Cancer	PTEN mutation	Estrogen Receptor Positive Breast Cancer	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2
PTEN mutation	Glioblastoma	PTEN mutation	Glioblastoma	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	LY3023414 Sensitive: C3 – Early Trials LY3023414 Sensitive : C3	LY3023414 Sensitive: C3 – Early Trials LY3023414 Sensitive : C3
PTEN mutation	Hormone Receptor Positive Breast Cancer	PTEN mutation	Hormone Receptor Positive Breast Cancer	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3	alpelisib Resistant: C3 – Early Trials alpelisib Resistant : C3
PTEN mutation	HER2 Negative Breast Cancer	PTEN mutation	HER2 Negative Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
PTEN mutation	Colorectal Cancer	PTEN mutation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3	abiraterone acetate + RG7440 Resistant: C3 – Early Trials abiraterone acetate + RG7440 Resistant : C3
PTEN mutation	Melanoma	PTEN mutation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PTEN mutation	Melanoma	PTEN mutation	Melanoma	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3	pembrolizumab + GSK2636771 Sensitive: C3 – Early Trials pembrolizumab + GSK2636771 Sensitive : C3
PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3	enzalutamide + CC-115 Sensitive: C3 – Early Trials enzalutamide + CC-115 Sensitive : C3
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3	talazoparib Sensitive: C3 – Early Trials talazoparib Sensitive : C3
PTEN mutation	Solid Tumor	PTEN mutation	Solid Tumor	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3	ARQ 751 Sensitive: C3 – Early Trials ARQ 751 Sensitive : C3
PTEN mutation	HER2 Negative Breast Cancer	PTEN mutation	HER2 Negative Breast Cancer	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
PTEN mutation	Solid Tumor	PTEN mutation	Solid Tumor	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3	CB-228 Sensitive: C3 – Early Trials CB-228 Sensitive : C3
PTEN mutation	Melanoma	PTEN mutation	Melanoma	vemurafenib Resistant: C4 – Case Studies vemurafenib Resistant : C4	vemurafenib Resistant: C4 – Case Studies vemurafenib Resistant : C4
PTEN mutation	Pancreatic Cancer	PTEN mutation	Pancreatic Cancer	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4	MK-2206 Sensitive: C4 – Case Studies MK-2206 Sensitive : C4
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	TAS-117 Sensitive: C4 – Case Studies TAS-117 Sensitive : C4	TAS-117 Sensitive: C4 – Case Studies TAS-117 Sensitive : C4
PTEN mutation	Glioblastoma	PTEN mutation	Glioblastoma	MLN4924 Resistant: D – Preclinical MLN4924 Resistant : D	MLN4924 Resistant: D – Preclinical MLN4924 Resistant : D
PTEN mutation	Glioma	PTEN mutation	Glioma	MLN4924 Resistant: D – Preclinical MLN4924 Resistant : D	MLN4924 Resistant: D – Preclinical MLN4924 Resistant : D
PTEN mutation	Prostate Cancer	PTEN mutation	Prostate Cancer	dasatinib + AZD8055 Sensitive: D – Preclinical dasatinib + AZD8055 Sensitive : D	dasatinib + AZD8055 Sensitive: D – Preclinical dasatinib + AZD8055 Sensitive : D
PTEN mutation	Colorectal Cancer	PTEN mutation	Colorectal Cancer	PARP inhibitor Resistant: D – Preclinical PARP inhibitor Resistant : D	PARP inhibitor Resistant: D – Preclinical PARP inhibitor Resistant : D
PTEN mutation	Breast Cancer	PTEN mutation	Breast Cancer	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D	CB-228 Sensitive: D – Preclinical CB-228 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	AZD6482 Resistant: D – Preclinical AZD6482 Resistant : D	AZD6482 Resistant: D – Preclinical AZD6482 Resistant : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	GSK2636771 Resistant: D – Preclinical GSK2636771 Resistant : D	GSK2636771 Resistant: D – Preclinical GSK2636771 Resistant : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	GDC-0941 Sensitive: D – Preclinical GDC-0941 Sensitive : D	GDC-0941 Sensitive: D – Preclinical GDC-0941 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D

PTEN mutation

Associations